C12N 2770/36132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2770/36132 (Use of virus as therapeutic agent, other than vaccine) appears on 16 US grants and 34 published applications in this corpus.
Search patents in C12N- Granted patents
- 16
- Published applications
- 34
- Assignees
- 18
- Inventors
- 65
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 2 | 1 |
| 2008 | 0 | 7 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 2 | 1 |
| 2013 | 1 | 1 |
| 2014 | 2 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 3 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 3 |
| 2021 | 0 | 2 |
| 2022 | 2 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of use of oncolytic virus like vesicles17 Mar 2026US 12,577,585 B2Carogen Corporation
- Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy12 Aug 2025US 12,383,589 B2Massachusetts Institute of Technology
- Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins24 Sep 2024US 12,097,257 B2New York University
- Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy8 Aug 2023US 11,717,548 B2Massachusetts Institute of Technology
- Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug1 Feb 2022US 11,234,968 B2Guangzhou Virotech Pharmaceutical Co., Ltd.
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy2 Jul 2026US 2026/0183354 A2SunVax mRNA Therapeutics Inc.
- Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy5 Mar 2026US 2026/0061013 A1Massachusetts Institute of Technology
- Alphavirus (Mayaro virus) Constructs Attenuated for Human and Method of its Use18 Dec 2025US 2025/0381263 A1Institut Pasteur de Montevideo
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy11 Sep 2025US 2025/0281557 A1SunVax mRNA Therapeutics Inc.
- Adenovirus for treatment of cancer13 Jun 2024US 2024/0189374 A1Elicera Therapeutics AB
Most cited
By later US patents
- Viral adjuvants48US 7,862,829 B2The University of North Carolina at Chapel Hill · 2011
- Treatment of neoplasms with viruses31US 8,105,578 B2Wellstat Biologics Corporation · 2012
- Methods and compositions for alphavirus replicons25US 8,961,995 B2The UAB Research Foundation · 2015
- Pharmaceutical composition for treatment of cancers4US 7,270,812 B22007
- Defective sindbis viral vectors3US 7,303,898 B2New York University · 2007